About
Antisense DNA therapeutics
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapySouthwestern U.S.
Team (4)
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
296
By Phase
PHASE1: 4PHASE1/PHASE2: 1PHASE2: 1
By Status
RECRUITING: 3ACTIVE_NOT_RECRUITING: 1WITHDRAWN: 1COMPLETED: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT04196257Lead Sponsor
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
PHASE1Recruiting
50 participants
Started: Aug 19, 2022 · Completed: Oct 31, 2027
NCT05190471Lead Sponsor
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
PHASE1Recruiting
48 participants
Started: Aug 16, 2022 · Completed: Sep 30, 2027
NCT04072458Lead Sponsor
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
PHASE1Active, not recruiting
30 participants
Started: Nov 5, 2020 · Completed: Apr 30, 2025
NCT02923986Lead Sponsor
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
PHASE1/PHASE2Withdrawn
Started: Sep 1, 2017 · Completed: May 27, 2020
NCT02781883Lead Sponsor
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
PHASE2Recruiting
108 participants
Started: May 31, 2016 · Completed: Dec 31, 2028
Locations (1)
Headquarters
Bellaire, TX, United States
Map
Loading map...